Literature DB >> 27249742

Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder.

Tracy T Batchelor1, Lim Soon Thye1, Thomas M Habermann1.   

Abstract

Primary central nervous system lymphoma, natural killer T-cell lymphoma nasal type, and post-transplant lymphoproliferative disorder are uncommon and complex lymphoproliferative disorders. These disorders present with different risk factors, have complex tumor characteristics, and require unique therapeutic interventions. These diseases require a multidisciplinary complex team approach. This article will update current management approaches and concepts.

Entities:  

Mesh:

Year:  2016        PMID: 27249742     DOI: 10.1200/EDBK_159030

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  4 in total

Review 1.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

Review 2.  Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.

Authors:  Fedaey Abbas; Mohsen El Kossi; Ihab Sakr Shaheen; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2020-02-28

3.  Primary diffuse large B-cell lymphoma of the CNS: a rare case of spontaneous remission.

Authors:  Fotini Debonera; Sunita Nasta; Maria Martinez-Lage; Stephen J Schuster; Donald E Tsai
Journal:  Int J Hematol Oncol       Date:  2017-11-20

4.  Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-immunotherapy.

Authors:  Hiroaki Inoue; Shinya Rai; Hirokazu Tanaka; J Luis Espinoza; Maiko Komori-Inoue; Hiroaki Kakutani; Shuji Minamoto; Takahiro Kumode; Shoko Nakayama; Yasuhiro Taniguchi; Yasuyoshi Morita; Takeshi Okuda; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
Journal:  Viruses       Date:  2020-04-08       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.